Lipoprotein and cholesterol metabolism in the brain involves metabolic pathways that are regulated independently of those in the peripheral circulation and tissues. The blood–brain barrier (BBB) restricts plasma lipids, including cholesterol and plasma lipoproteins, from entering or leaving the central nervous system (CNS). In the CNS, cholesterol is synthesized by astrocytes, oligodendrocytes, microglia, and to a lesser extent neurons. CNS cholesterol homeostasis is maintained by 24S-hydroxycholesterol produced by neurons. CNS lipoproteins redistribute cholesterol and lipids to neurons and other brain cells to maintain neuronal plasticity, which requires repair and remodeling of membranes, organelle biogenesis, and synaptogenesis. ApoE is critical in this process through the formation of apoE-enriched CNS lipoproteins that are high-density lipoprotein (HDL) like but are unlike the major apo AI–enriched HDL in plasma.

Cholesterol Synthesis and Metabolism in the CNS
The brain is the most cholesterol-rich organ; with only 2% of body mass, it contains ≈20% of the body’s cholesterol. About 70% is in myelin, and ≈30% is metabolically active and found in membranes of glial cells and neurons, where it undergoes recycling primarily for neuronal repair and remodeling.1,2 Cholesterol in the brain is synthesized from acetate in situ.1 It is essentially no cholesterol that enters the brain from the peripheral circulation. During early development, oligodendrocytes synthesize large quantities of cholesterol for myelination. In adults, when myelination is complete, glial cells and, to a lesser extent, neurons account for the steady-state production of cholesterol. As already stated, cholesterol recycling and redistribution involve an apoE-mediated lipoprotein pathway unique to the CNS. Again, the brain uses a unique mechanism whereby cholesterol is turned over, and excess sterols are ultimately delivered to the liver for secretion into the bile. Cholesterol itself does not exit the brain but instead is converted to a metabolite 24S-hydroxycholesterol. 24S-hydroxycholesterol is much more soluble than cholesterol and is thought to diffuse across the BBB to enter the plasma, where it is picked up by plasma lipoproteins, transported to the liver, metabolized to...
Lipoprotein Synthesis and Metabolism in the CNS in Humans

Lipoproteins and their metabolism differ in the peripheral circulation and the CNS (Figure 1). ApoB-containing hepatic and intestinal particles not found in the CNS, including very low-density lipoproteins (VLDL), intermediate-density lipoproteins, LDL, and chylomicrons, are critical for lipid transport and lipid metabolism in plasma. They participate in absorption of dietary lipid (triglycerides), lipid transport to peripheral cells, generation of fatty acids for storage, and lipid metabolism.12

Plasma HDLs contain primarily apo AI; apo AI, apoE, apo AIV, and apoCs are present at lower levels. Generated from the surface of triglyceride-rich lipoproteins during lipolysis and synthesized by hepatocytes and intestinal enterocytes, apo AI forms a pool of HDL discs—lipid-poor pre-β-HDL that initiate formation of mature HDL particles (HDL3 and HDL4), which grow larger and more enriched in cholesterol and cholesteryl esters. Unesterified cholesterol and phospholipids are transferred by the ATP-binding cassette transporter 1 (ABCA1) in peripheral tissues to HDL; unesterified cholesterol is esterified by lecithin–cholesterol acyltransferase (LCAT). Newly secreted apo AI interacts with ABCA1 primarily on hepatocytes and enterocytes (hepatic ABCA1 activity accounts for ≈80% of HDL formation in vivo).13 Plasma HDLs participate in reverse cholesterol transport—delivery of excess cholesterol by the cholesteryl ester transfer protein (CETP) to the liver for excretion. Plasma HDLs are a reservoir for apoE, which is transferred to chylomicrons and VLDL to mediate their clearance by the LDL receptor. Although apoE-containing HDLs (HDL1) constitute ≤10% of total HDLs, they have not been extensively studied.14 In lower animals, HDL1 can be a major lipoprotein class, especially in cholesterol-fed animals. HDL1 are cholesteryl ester enriched and larger than HDL, or HDL2.15 In cultured macrophages that synthesize and secrete apoE and are exposed to LCAT, apoE facilitates cholesteryl incorporation into HDL particles to form cholesteryl ester–rich cores.14–16 Particle size (20 nm) corresponds to the layers of cholesteryl ester in the core.16

ApoE is the major apolipoprotein regulating CNS lipid metabolism and, along with apo AI, forms HDL-like particles that help to redistribute cholesterol and phospholipids to cells for repair and remodeling (triglyceride is scarce or absent in the CNS; Figure 1). Apo AI is transferred from plasma to the CNS and is not synthesized in the brain, but apoE is synthesized in the CNS.17 CNS lipoproteins differ from plasma

---

**Table 1. Human Plasma and CSF Levels**

<table>
<thead>
<tr>
<th></th>
<th>ApoE, mg/dL</th>
<th>Apo AI, mg/dL</th>
<th>Albumin, g/L</th>
<th>IgG, g/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td>≈3–6</td>
<td>90–140</td>
<td>40.8±6.01</td>
<td>9.3±1.82</td>
</tr>
<tr>
<td>CSF</td>
<td>1.02</td>
<td>0.33</td>
<td>0.30</td>
<td>0.0206</td>
</tr>
<tr>
<td></td>
<td>0.9±0.311</td>
<td>0.37±0.181</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≈0.711</td>
<td>0.37±0.081</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% of plasma level</td>
<td>≈10–20</td>
<td>≈0.3</td>
<td>≈0.75</td>
<td>≈0.3</td>
</tr>
</tbody>
</table>

CSF indicates cerebrospinal fluid.

---

**Table 2. Human ApoE Levels (mg/dL) by ApoE Phenotype**

<table>
<thead>
<tr>
<th>ApoE phenotype</th>
<th>Plasma</th>
<th>Plasma</th>
<th>CSF</th>
</tr>
</thead>
<tbody>
<tr>
<td>ApoE2/2</td>
<td>≈5</td>
<td>8.5</td>
<td></td>
</tr>
<tr>
<td>ApoE3/2</td>
<td>≈3.5</td>
<td>5.4</td>
<td>0.89±0.26</td>
</tr>
<tr>
<td>ApoE4/2</td>
<td>—</td>
<td>5.1</td>
<td>0.75±0.25</td>
</tr>
<tr>
<td>ApoE3/3</td>
<td>≈2.2</td>
<td>4.0</td>
<td>0.69±0.25</td>
</tr>
<tr>
<td>ApoE4/3</td>
<td>≈2.1</td>
<td>3.6</td>
<td>0.64±0.20</td>
</tr>
<tr>
<td>ApoE4/4</td>
<td>≈2.0</td>
<td>3.0</td>
<td>0.62±0.23</td>
</tr>
</tbody>
</table>
HDL. In the CNS, apoE delivers cholesterol and other lipids to cells through interactions with ≥1 members of the LDL receptor family. Nevertheless, enzymes, transporters, and receptors similar to those in the periphery are used in CNS lipoprotein formation and metabolism, including LCAT, CETP, ABCA1, ABCG1, ABCG4, and the LDL receptor and family members.

CNS ApoE: Sites of Synthesis, Secretion, and Regulation

ApoE structure and function have been studied extensively in the periphery and in the brain, and several roles have been defined.20–22 The brain is the second most common site of apoE production (liver accounts for 75%); various CNS cells are involved, particularly astrocytes, including specialized astrocytes (Bergmann glia, tanyocytes, pituicytes, and retinal Müller cells).24 Primary cultures of mouse astrocytes pulsed with [35S]methionine secrete apoE-containing HDL-like particles.25

Brain apoE expression was mapped in mice by inserting enhanced green fluorescent protein (EGFP) into the apoE gene to create apoE transgenic mice.26 In wild-type and apoE targeted replacement mice, cortical and hippocampal apoE levels were 20% lower than in wild-type mice.27 Thus, neurons likely synthesize and secrete as much as 20% of CNS apoE.

Furthermore, normally neurons are uniquely poised to rapidly produce apoE. Neurons contain a splicing variant of apoE mRNA not found in astrocytes or hepatocytes.31 In wild-type and apoE targeted replacement mice, cortical and hippocampal apoE levels were 20% lower than in wild-type mice.27 Thus, neurons likely synthesize and secrete as much as 20% of CNS apoE.

ApoE is produced by injured or stressed neurons.26 In EGFPapoE mice treated with kainic acid, injured neurons produced high levels of apoE as confirmed by EGFP expression and in situ hybridization of apoE mRNA in the hippocampus. Under normal physiological conditions, conditional deletion of Apoe, specifically from neurons in apoE targeted replacement (knockin) mice, decreased cortical and hippocampal apoE levels by 20%.28 Thus, neurons likely synthesize and secrete as much as 20% of CNS apoE.
the critical role of apoE production, presumably for redistribution of cholesterol for cellular repair and maintenance and possibly as a transcription factor.32

Neuronal apoE production is regulated at least in part by an astrocyte-secreted factor or factors through the extracellular signal–regulated kinase pathway. In neuronal cells expressing human apoE3 or apoE4, astrocyte-conditioned medium increases apoE expression 4–10-fold.33 Stress- and injury-induced upregulation of neuronal apoE production could be partly mediated by astrocyte activation (astrocytosis) after acute injury, including traumatic brain injury, oxidative stress, and amyloid-β (Aβ) accumulation. In EGFP-ae3 mice, smooth muscle cells surrounding large blood vessels in the CNS and cells of the choroid plexus also produce apoE26 as do cultured arterial smooth muscle cells.34

**Apo AI in the CNS**

Apo AI is not produced in the CNS but is transferred from the peripheral circulation to the CSF to help redistribute cholesterol in the brain. Intravenously injected recombinant, fluorescently labeled human apo AI rapidly appears in CSF.35 Apo AI is primarily transferred in the choroid plexus. Cultured primary human choroid plexus epithelial cells bind, internalize, and transfer apo AI across the cells. Although the choroid plexus contains numerous specific transporters, the apo AI transporter is not known.35

**Human CSF Lipoproteins**

The major apolipoproteins in the CSF are apoE and apo AI, with lesser amounts of apoAI, apoS, apoE, and apoD. CSF lipoproteins float by ultracentrifugation at d=1.063 to 1.21 g/mL with the majority at d=1.09 to 1.15 g/mL. They tend to be small and spherical (10–20 nm), like plasma HDL, but are unique HDL-like particles. CSF lipoproteins fractionated by density gradient ultracentrifugation include both apoE and apo AI particles.36 These particles primarily contain phospholipid and cholesterol (≈35% unesterified versus 25% in plasma HDL). Besides phosphatidylcholine (the major phospholipid), the CSF lipoproteins contain more phosphatidylethanolamine. The reason why is unclear. ApoE is sialylated more in CSF than in plasma. ApoE possesses a single carbohydrate attachment site at threonine-194.37 CSF lipoproteins bind avidly to fibroblast LDL receptors (high-affinity binding, >20-fold higher than LDL for the receptors).36

Subfractionation of CSF lipoproteins by apoE and apo AI immunoaffinity columns revealed 2 distinct particles.36 One contained predominantly apoE and was largely spherical (15.4±3 nm) with a few disc-like particles. The other contained apo AI and was spherical and smaller (12.9±2.1 nm). In another study,38 CSF lipoproteins separated by gel filtration had an elution profile equivalent to plasma HDL. Immunoaffinity chromatography with anti-apoE then anti–apo AI resolved 4 lipoproteins: CSF-Lp apoE, CSF-Lp apo AI, CSF-Lp apoE/ AI, and Lp (with neither apoE nor apo AI). All particles contained apoD and apoJ. Lp apoE, Lp apo AI, and Lp apoE/AI had similar lipid composition (≈60% protein, 20% to 30% phospholipid, and 14% to 17% cholesterol). Lp apoE particles were larger (18–20 nm) than Lp apoE/AI particles (13–20 nm) and more lipid rich (lipid:protein, 0.76:1). Lp apo AI particles were smaller (13–18 nm).

**Isoform-Specific Effects on Human CSF ApoE Levels**

Plasma levels of apoE vary with apoE genotype (apoE2>apoE3>apoE4; Tables 1 and 2).38 In ≈700 healthy controls, a sensitive ELISA for apoE90 showed a strong gradient (apoE2/2 highest; apoE4/4 lowest). Total apoE was less abundant in apoE4 carriers than in noncarriers (5.6±2.4 versus 17.4±3.1 mg/dL; P<0.001). This gradient was also seen in cognitively impaired subjects.

In >400 cognitive normal subjects, mean plasma apoE was 5.7 mg/dL and total CSF apoE was 0.7 mg/dL (range, 0.6–0.9 mg/dL; highest in apoE2 and lowest in apoE4 carriers; Tables 1 and 2). In plasma, this gradient reflects decreased LDL receptor binding of apoE2 (and thus higher plasma levels) and the preference of apoE4 for VLDL (accelerates hepatic clearance and results in lower levels). The higher brain levels of apoE2 could also reflect impaired receptor binding. However, the lower apoE4 levels likely reflect increased degradation caused by its unique structural features. ApoE4 preferentially forms a molten globule intermediate that makes it less stable than apoE3,41 and its amino terminus interacts with the carboxyl terminus through an ionic interaction between arginine-61 (Arg-61) and glutamic acid-255 (Figure 2A).42 Domain interaction causes the preferential binding of apoE4 to VLDL in plasma and increases hepatic clearance. In the brain, low apoE4 levels are influenced by the domain interaction,

Figure 2. Models of apoE3 and apoE4 structure. A, ApoE4 displays a unique property, referred to as domain interaction, that involves an ionic interaction between arginine (Arg)-61 and glutamic acid (Glu)-255. ApoE3 undergoes domain interaction to a lesser degree. Domain interaction is associated with many altered functional properties that distinguish apoE4 from apoE3. B, Domain interaction can be blocked by small molecules that prevent the ionic interaction and convert apoE4 to an apoE3-like molecule, both structurally and functionally. Apo4SC indicates apoE4 structure corrector; Cys, cysteine; and Glu, glutamic acid.

---

**References**

32. Neuronal apoE production is regulated at least in part by an astrocyte-secreted factor or factors through the extracellular signal–regulated kinase pathway. In neuronal cells expressing human apoE3 or apoE4, astrocyte-conditioned medium increases apoE expression 4–10-fold. Stress- and injury-induced upregulation of neuronal apoE production could be partly mediated by astrocyte activation (astrocytosis) after acute injury, including traumatic brain injury, oxidative stress, and amyloid-β (Aβ) accumulation.

33. In EGFP-ae3 mice, smooth muscle cells surrounding large blood vessels in the CNS and cells of the choroid plexus also produce apoE2 as do cultured arterial smooth muscle cells.

34. Apo AI is not produced in the CNS but is transferred from the peripheral circulation to the CSF to help redistribute cholesterol in the brain. Intravenously injected recombinant, fluorescently labeled human apo AI rapidly appears in CSF. Apo AI is primarily transferred in the choroid plexus. Cultured primary human choroid plexus epithelial cells bind, internalize, and transfer apo AI across the cells. Although the choroid plexus contains numerous specific transporters, the apo AI transporter is not known.

35. Human CSF lipoproteins: CSF-Lp apoE, CSF-Lp apo AI, CSF-Lp apoE/AI, and Lp (with neither apoE nor apo AI). All particles contained apoD and apoJ. Lp apoE, Lp apo AI, and Lp apoE/AI had similar lipid composition (≈60% protein, 20% to 30% phospholipid, and 14% to 17% cholesterol). Lp apoE particles were larger (18–20 nm) than Lp apoE/AI particles (13–20 nm) and more lipid rich (lipid:protein, 0.76:1). Lp apo AI particles were smaller (13–18 nm).

36. Isoform-Specific Effects on Human CSF ApoE Levels: Plasma levels of apoE vary with apoE genotype (apoE2>apoE3>apoE4; Tables 1 and 2). In ≈700 healthy controls, a sensitive ELISA for apoE showed a strong gradient (apoE2/2 highest; apoE4/4 lowest). Total apoE was less abundant in apoE4 carriers than in noncarriers (5.6±2.4 versus 17.4±3.1 mg/dL; P<0.001). This gradient was also seen in cognitively impaired subjects.

37. In >400 cognitive normal subjects, mean plasma apoE was 5.7 mg/dL and total CSF apoE was 0.7 mg/dL (range, 0.6–0.9 mg/dL; highest in apoE2 and lowest in apoE4 carriers; Tables 1 and 2). In plasma, this gradient reflects decreased LDL receptor binding of apoE2 (and thus higher plasma levels) and the preference of apoE4 for VLDL (accelerates hepatic clearance and results in lower levels). The higher brain levels of apoE2 could also reflect impaired receptor binding. However, the lower apoE4 levels likely reflect increased degradation caused by its unique structural features. ApoE4 preferentially forms a molten globule intermediate that makes it less stable than apoE3, and its amino terminus interacts with the carboxyl terminus through an ionic interaction between arginine-61 (Arg-61) and glutamic acid-255 (Figure 2A). Domain interaction causes the preferential binding of apoE4 to VLDL in plasma and increases hepatic clearance. In the brain, low apoE4 levels are influenced by the domain interaction.
which may be caused by enhanced astrocyte degradation. The lower apoE4 levels and thus lower levels of cholesterol transport could affect cholesterol homeostasis and neuronal plasticity.

### Mouse Models of Human ApoE Metabolism in the Brain

#### CSF ApoE Levels in Mouse Models

In an extensive, well-controlled study, plasma and CSF levels were examined in apoE2/2, apoE3/3, and apoE4/4 targeted replacement mice. To eliminate spurious results from masked apoE epitopes, multiple methods were used to detect and quantitate apoE, including detergent extraction of plasma, CSF, and brain tissue. Despite similar mRNA levels, plasma levels of apoE2 were the highest and apoE4 were the lowest. CSF apoE levels in the mice had the same gradient as seen in human CSF (apoE2>apoE3>apoE4; Tables 3 and 4). An additional study of targeted replacement mice confirmed these findings, showing a 3- to 4-fold difference between apoE2 and apoE4 levels in CSF, which was demonstrated by microdialysis probes in the hippocampus of targeted replacement mice. The gradient of apoE levels also occurs in frontal cortex and hippocampus (Tables 3 and 4).

Some studies reported similar apoE levels in apoE4 and apoE3 targeted replacement mice and higher apoE levels in apoE3/4 humans. These discrepancies could reflect masked epitopes from variable lipidation and poor extraction from brain samples. Detergent extraction is essential, and data from immunoassays and Western blotting must be analyzed. Moreover, apoE aggregates readily.

Mechanisms for the lower apoE4 levels were studied in cultured primary astrocytes from targeted replacement mice. ApoE4/4 mouse astrocytes secreted 28% less apoE and ≤50% less cholesterol than apoE3/3 astrocytes: Cellular retention of apoE4 was not different; however, in pulse-chase studies, apoE4 disappeared more rapidly than apoE3 (half-life, 49 versus 96 minutes; enhanced degradation of apoE4 will be discussed in greater detail later).

#### ApoE Structure Modulates ApoE Levels and Metabolism

Mouse apoE has arginine at the site equivalent to residue 112 in human apoE4 but has threonine at the site equivalent to residue 61 and thus lacks domain interaction. The same is true for all animals except humans. Arg-61 mouse apoE generated by gene targeting displays domain interaction similar to human apoE4 and has lower plasma levels than wild-type mouse apoE, and Arg-61 mice have pathological characteristics and behavioral impairments similar to those of mice expressing human apoE4.

In the brain, Arg-61 mouse apoE behaves like human apoE4. Despite similar mRNA levels, Arg-61 mouse apoE levels are 43% lower overall than wild-type mouse apoE, which behaves more like apoE3, and 33% to 47% lower in cortex, hippocampus, and cerebellum regardless of age or sex. In targeted replacement mice, apoE4 levels are 28% lower than apoE3 levels and 26% to 37% lower in cortex, hippocampus, and cerebellum. In primary cultures of astrocytes, secretion of Arg-61 mouse apoE is 46% lower than wild-type mouse apoE, and apoE3/4 cells secrete 25% less apoE than apoE3. Thus, domain interaction that occurs in the context of Arg-112 and Arg-61 is the critical structural feature of apoE contributing to the lower apoE levels in the CNS as displayed by the expression of human apoE4 or induced by replacing the normally occurring threonine with arginine at the site equivalent to residue 61 in mouse apoE. Wild-type mouse apoE does not faithfully mimic either human apoE4 or apoE3.

#### ApoE4 Structure Targets It for Degradation and Decreased Lipid Transport

Domain interaction leads to intracellular degradation and altered lipid-binding capacity. Arg-61 mouse apoE (surrogate for apoE4) elicits an ER stress response in primary cultured astrocytes from the Arg-61 mice, but wild-type mouse apoE (surrogate for apoE3) does not. Arg-61 mouse apoE was targeted for degradation, and markers of the unfolded protein response in all 3 unfolded protein response pathways were upregulated. ApoE4 does not activate the ER stress pathway in neurons.

As discussed, neurons are poised for apoE synthesis but synthesize less apoE until they are injured or stressed by aging, neurotoxins, ischemia, oxidative stress, and likely other environmental and genetic factors that necessitate redistribution of cholesterol and other lipids for repair and remodeling. However, because of domain interaction, apoE4 is recognized by a neuron-specific protease that degrades it to a greater extent than apoE3, generating neurotoxic carboxyl-terminal fragments of 12 to 29 kDa. These fragments escape the secretory pathway, stimulate τ-phosphorylation, and cause mitochondrial dysfunction. The fragmentation is blocked by site-directed mutagenesis (Arg-61 to threonine) or small-molecule structure correctors that prevent domain interaction (Figure 2B).

ApoE4 synthesis by astrocytes is associated with lipoprotein particles with various degrees of lipidation.
Isoform-specific differences in phospholipid and cholesterol secretion from primary cultured astrocytes from targeted replacement mice expressing human apoE3 or apoE4 have been characterized in detail. Similar levels of apoE3 and apoE4 were released, and the particles were of similar size, but apoE3 was associated with a 2- to 3-fold greater release of phospholipid and cholesterol. Thus, apoE3 delivers more cholesterol and phospholipids to cells. Likewise, because of the domain interaction, neuronal cells transfected with apoE4 release ≈25% less phospholipid than cells expressing apoE3.61 When apoE4 domain interaction was disrupted by insertion of threonine at residue 61, phospholipid release from apoE4–threonine–61– and apoE3-expressing cells was the same and greater than from apoE4-expressing cells.

ApoE isoforms differ in their lipid binding and lipoprotein preferences.22,42,64 ApoE3 binds to small HDLs, whereas apoE4 binds to large VLDLs—at least partially because of domain interaction, which changes the exposure or orientation of the lipid-binding region. When domain interaction is blocked, the lipoprotein-binding preference of apoE4 resembles that of apoE3.

In sum, apoE4 is more susceptible to intracellular degradation in astrocytes and neurons, is present at lower levels in the CNS and CSF, and delivers cholesterol and phospholipid to neurons less efficiently (Figure 3). These alterations are associated with neuropathology, including AD, traumatic brain injury, stroke, and other apoE4-associated neurological disorders.

Role of ABCA1 in HDL Formation

Apo AI, the major apolipoprotein in plasma HDL metabolism, participates in a cholesterol redistribution process called reverse cholesterol transport (Figure 1). Lipidation of apo AI in peripheral tissues, including hepatocytes and enterocytes, involves ABCA1-mediated transport of cholesterol and phospholipid from cell membranes (Figure 1).13 ABCA1 is found in a wide range of cells in the body, including astrocytes and neurons in the brain.

In the CNS, ABCA1 participates in cholesterol efflux to apoE to form HDL-like apoE-containing particles enriched in phospholipid and unesterified cholesterol.65 In apoE-producing macrophages, apoE interacts with ABCA1 to form unesterified cholesterol–rich HDL; apo AI, if present, enhances the efficiency of this process.66 ABCA1 is important in mouse CNS,67,68 ABCA1 deletion reduces apoE levels in plasma, brain, and CSF by >80% and is associated with the formation of small apoE-containing lipoproteins. In addition, cultured astrocytes lacking ABCA1 form only small, cholesterol-poor apoE-containing lipoproteins. Thus, ABCA1 in mice is critical for apoE lipoprotein and HDL formation.

The importance of ABCA1 in human CNS lipid metabolism is not completely clear. In Tangier disease, mutations in both alleles and the absence of ABCA1 activity reduce plasma HDL cholesterol and apo AI by 40% to 50% and decrease apo AI HDL lipidation.69,70 Plasma apoE levels are unchanged or increased.71 However, Tangier disease patients do not have CNS problems (eg, no increased risk of dementia). A study of patients with 10 single-nucleotide polymorphisms in ABCA1, including those associated with altered plasma HDL levels, failed to show an association with CNS apoE levels.72 If ABCA1 activity was rate limiting for apoE–HDL lipidation, one would expect decreased apoE–HDL levels as observed in the mice.

Alternatively, other transporters could assume the role of ABCA1 in the CNS. For example, ABCA7, a relative of ABCA1, serves as a phospholipid transporter that seems to mediate cholesterol removal.73 Importantly, ABCA7 is highly expressed in the brain, and in a genome-wide association study, it was shown to be a risk factor for AD.74 As will be discussed, ABCG1 and ABCG4 could also compensate for a deficiency of ABCA1 activity and mediate apoE–HDL lipidation.

Role of ABCG1 in Peripheral Tissues and the CNS

In cultured cells, ABCA1 and ABCG1 lipidate nascent HDL, possibly with ABCA1 initiating cholesterol and phospholipid

![Figure 3. ApoE4 is a major therapeutic target to prevent or slow Alzheimer disease and several other neurodegenerative disorders. ApoE4 is synthesized primarily by astrocytes but to a lesser extent by neurons (injury to neurons stimulates apoe production). I, ApoE4 synthesis by neurons triggers neuron-specific proteolysis, generating a series of neurotoxic fragments that escape the secretory pathway and stimulate -phosphorylation and mitochondrial dysfunction. The unique structural feature of apoE4—domain interaction—is responsible for stimulating the proteolysis, and blocking apoE4 domain interaction with apoE4 structure correctors prevents the formation and the neurotoxic effects of the fragments and protects against neurodegeneration and impaired cognition. II, The accelerated degradation of apoE4 by astrocytes (and to a lesser extent the increased proteolysis of apoE4 in neurons) results in decreased apoE4 levels in the cerebrospinal fluid (CSF) and central nervous system (CNS). It has been postulated that this contributes to decreased amyloid- (Aβ) clearance.] In addition to lower levels of apoE4, apoE4 has a decreased lipid-binding capacity. ApoE4 domain interaction is also associated with decreased apoE4 levels and decreased affinity for lipids. ApoE4 structure correctors can restore the apoE4 levels and enhance lipid binding. ER indicates endoplasmic reticulum.
transfer to apo AI or apoE to form discs, which are further lipidated by ABCG1. However, neither deletion nor overexpression of ABCG1 in mice affects plasma lipid levels significantly. Interestingly, ABCG1 and its relative ABCG4 may function more importantly in the CNS than the periphery. Both are widely expressed in neurons and astrocytes (ABCG4 primarily expressed in the brain). These transporters display overlapping roles in sterol efflux from cells to HDLs. Deletion of either ABCG1 or ABCG4 did not affect CNS sterol levels, whereas deletion of both transporters resulted in a 2- to 3-fold increase of sterols, including desmosterol, lanosterol, lathosterol, and 27-OH cholesterol. Thus, the variety of lipid transporters displaying both unique and overlapping roles in efflux and transport within the CNS further illustrates the critical role of lipid homeostasis occurring in situ and restricted by the BBB.

**Role of LDL Receptor Family Members in ApoE Delivery of Cholesterol to CNS Cells**

The LDL receptor and the LDL–related protein 1 are primarily responsible for lipoprotein binding and cholesterol delivery by apoE to neurons and glia. The VLDL receptor and apoE receptor 2 participate in reelin modulation of neuronal development of cerebral cortex and in reelin-mediated intracellular signaling but not cholesterol transport. LDL receptors are most highly expressed in glia and to a lesser extent in neurons. LDL receptor–related protein 1 receptors are more highly expressed in neurons. Heparan sulfate proteoglycans on neuronal and glial cell membranes may facilitate binding to the LDL receptor–related protein 1 or to sequester apoE molecules to enrich the lipoproteins for receptor-mediated uptake as in the liver. In mice, brain and CSF apoE levels are increased by LDL receptor deletion and decreased by LDL receptor overexpression. Likewise, conditional deletion of LDL receptor–related protein 1 in forebrain neurons increases apoE levels.

**Role of LCAT in Cholesterol Ester Formation in the CNS**

LCAT transfers a fatty acid from phospholipid to unesterified cholesterol to form cholesterol esters. Apo AI activates LCAT to a greater extent than apoE. In an artificial recombinant system lacking apo AI, apoE4 was less efficient in activating LCAT to form cholesteryl esters and in converting discoidal particles to spherical apoE-containing lipoproteins. The unique structure and conformation assumed by apoE4 on these apoE discs and small particles may alter the access of LCAT to the phospholipid acyl chains. Loss of formation of LCAT in apoE4-containing lipoproteins could impair maturation of CNS HDL, limiting the availability of cholesterol and other lipids for cells. Core formation is essential for HDL to optimally acquire cholesterol from cells and to increase its cholesterol-carrying capacity.

**Role of CETP in the CNS**

In plasma, CETP mediates cholesteryl ester transfer from HDL to lower density lipoproteins during reverse cholesterol transport. In human CSF, cholesteryl ester transfer activity is present at a concentration of ∼12% that in plasma, indicating that it is made in the brain. CETP activity is present in culture medium from neuroblastoma cells, astrocytes, and choroid plexus. Its role in the CNS is undefined. There are no lower density lipoproteins (eg, LDL) to serve as cholesteryl ester acceptors and no triglyceride-rich lipoproteins (eg, VLDL) for exchange of triglyceride for cholesteryl esters. In a highly artificial system of apoE-recombinant lipid discs, CETP caused apoE-containing lipoproteins to fuse, forming large particles. Thus, CETP may facilitate cholesteryl ester transfer among the CNS lipoproteins, resulting in fusion of apoE-and apo AI-containing particles, or its function could be unrelated to CNS lipoprotein metabolism.

**Other Apolipoproteins in the Brain and CSF**

**Apol**

ApoJ (clusterin) is a 75- to 80-kDa glycoprotein in the plasma HDL fraction and in several tissues, including brain. Normally produced by astrocytes, apoJ is markedly upregulated after stress or injury and produced by both astrocytes and neurons. In traumatic brain injury, this upregulation helps protect against oxidative stress and neuroinflammation. However, apoJ seems to play multiple roles in complement activation, oxidative stress, apoptosis, and cancer. It also serves as a chaperone in protein unfolding pathways and disposal of misfolded proteins. Much more needs to be learned about apoJ’s role in cholesterol transport and lipid delivery to CNS cells.

**ApoD**

ApoD, a 29-kDa protein that is transported on plasma HDL, has little homology with other apolipoproteins involved in lipid transport and is a member of the lipocalin family. It is produced in the brain and is associated with CSF HDL. ApoD is produced by astrocytes and oligodendrocytes. Its importance as a cholesterol transporter is unknown. ApoD has been shown to be cardioprotective against experimentally induced myocardial infarction in mice and can protect cultured cardiomyocytes from hypoxia by inhibiting oxidation. ApoD might play such a role in the brain where neurodegeneration is often accompanied by oxidative stress.

**ApoE-Associated Neuropathology**

AD, the leading cause of dementia, is increasing in prevalence secondary to aging populations worldwide. No effective therapy to prevent or reverse the cognitive impairment exists. During the past 25 years, the amyloid hypothesis has been the main AD research focus; however, several clinical trials using a variety of drugs to decrease amyloid plaques and the formation of Aβ peptides have failed. Undoubtedly, multiple factors involving several pathways must be considered in AD pathogenesis. This includes targeting apoE4 as a therapeutic approach.

ApoE4 is the major genetic risk factor for AD (65%–80% of all patients with AD have at least 1 apoE4 allele). ApoE4 increases the risk many fold and decreases the age of onset by 8 years for each apoE4 allele. It also plays a key role in poor clinical outcome after traumatic brain injury.
and stroke and in severity or progression in frontotemporal dementia, Lewy body disease, and other neurological disorders. ApoE4 is associated with deposition of amyloid; however, it remains to be proved that amyloid or Aβ is causative. Clearly, amyloid pathology does not explain the apoE4-associated neuropathology seen in the neurological disorders lacking amyloid pathology.

ApoE is envisioned to affect 2 major pathways affecting neurodegeneration: (1) a direct effect of apoE4 expression in neurons on the generation of neurotoxic fragments and (2) an indirect effect with lower levels of apoE4 and decreased lipid transport in the CNS associated with apoE4 (Figure 3). The unique structure of apoE4 (ie, domain interaction) drives these outcomes.

Our working hypothesis is that apoE4 sets the stage for various second hits (eg, aging, oxidative stress, excitotoxicity, ischemia, traumatic brain injury, and increased Aβ) that injure or stress neurons. Injured neurons synthesize apoE (Figure 3). However, apoE4 undergoes enhanced neuron-specific proteolysis, which generates neurotoxic fragments (≈12–29 kDa) that enter the cytosol, causing τ-hyperphosphorylation and mitochondrial dysfunction and ultimately neurodegeneration. Fragments containing the receptor-binding region (residues 136–150) and the lipid-binding region (residues 240–270) are the minimal structure of apoE responsible for neurotoxicity. The receptor-binding region serves as a protein translocation domain, and the lipid-binding region mediates fragment interaction with mitochondria. The initial proteolytic cleavage results in the formation of a 29-kDa fragment lacking the carboxyl-terminal 27 to 30 amino acids; subsequent cleavage removes various regions of the amino terminus. Blocking apoE4 domain interaction by site-directed mutagenesis (Arg-61 to threonine) or by small molecules (apoE structure correctors) prevents the ionic interaction of Arg-61 and Glu-255, the generation of neurotoxic fragments, and the detrimental effects of apoE4 in cultured neurons and in apoE4 transgenic and targeted replacement mouse models. Preclinical studies to develop apoE structure correctors as a therapeutic approach to prevent apoE4-associated neuropathology are in progress. Furthermore, inhibiting the neuronal protease would be an additional approach to preventing the generation of the apoE4 neurotoxic fragments.

An alternative therapeutic approach targets the lower levels and impaired lipida tion of apoE4 in the CNS (Figure 3). ApoE4 is degraded more effectively than apoE3/2 in both astrocytes (ER stress activation) and neurons (neuron-specific proteolysis). The result is lower levels of apoE4. ApoE4 also displays a lower lipid-binding capacity and lower affinity for lipids. Thus, apoE4 is associated with decreased lipid transport in the CNS and possible inefficient neuronal repair and remodeling. Importantly, both of these processes—apoE levels and lipida tion—are controlled by apoE4 domain interaction. ApoE4 conformation and its stability are responsible for the differences in lipid and lipoprotein binding. Blocking apoE4 domain interaction prevents neuronal and astrocytic degradation and allows enhanced lipida tion to occur.

Modulation of this pathway includes stimulating apoE expression with bexarotene, a retinoic x receptor agonist. An initial study with bexarotene decreased amyloid plaques and improved cognitive function in an AD mouse model. Such agonists alter the expression not only of apoE but also of ABCA1 and numerous other proteins. It remains to be determined whether increasing apoE4 is beneficial, or, more likely, detrimental. Other groups are considering approaches to enhance apoE4 lipidation by modulating ABC transporter activity. At present, there is no way to selectively enhance the activity of ≥1 of the lipid transporters in the CNS. The rationale behind enhancing apoE4 lipidation is the possibility that apoE4 HDL may have an enhanced ability to clear Aβ in the CNS; however, this remains to be proven.

Clearly, elucidation of apoE structure and function has led to understanding isoform-specific effects in normal and pathological processes. Unraveling CNS lipid and lipoprotein metabolism has contributed to the development of critically important therapeutic approaches in treating/preventing apoE4-associated neuropathology.

**Acknowledgments**

We thank Sylvia Richardson and Charlotte Pfeifer for article preparation, Stephen Ordway and Gary Howard for editorial assistance, and John C.W. Carroll for graphics.

**Sources of Funding**

This work was supported, in part, by the award (number 101786) from The Wellcome Trust Seeding Drug Discovery.

**Disclosures**

Dr Mahley is a shareholder and serves on the scientific advisory board and as a consultant for E-Scape Bio, Inc.

**References**


• Central nervous system lipoproteins and their metabolism are unique, reflecting the isolation of the brain from the peripheral circulation by the blood–brain barrier.
• ApoE is synthesized in the brain, forms high-density lipoprotein–like particles, and is responsible for the transport and redistribution of cholesterol to neurons and other cells for repair and remodeling.
• ApoE has isoform-specific effects on cholesterol homeostasis under normal and neuropathological conditions. ApoE4 is less abundant, has less affinity for high-density lipoprotein–like particles, and transports less cholesterol than apoE3 or apoE2.
• Unique structural features of apoE4, including domain interaction (ionic interaction between arginine-61 and glutamic acid-255) and conformational instability, are responsible for these effects.
• Domain interaction accelerates degradation in astrocytes under normal conditions, and in injured neurons it is associated with neuropathology from neurotoxic fragments of apoE4. Small-molecule structure correctors that block apoE4 domain interaction convert apoE4 to apoE3-like molecules and block the detrimental effects of apoE4, including the generation of neurotoxic fragments.

Highlights
Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism

Robert W. Mahley

Arterioscler Thromb Vasc Biol. published online May 12, 2016;
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/early/2016/05/12/ATVBAHA.116.307023

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/